cse vgw otc vgwcf
play

CSE: VGW OTC: VGWCF CORPORATE PRESENTATION MARCH 2019 DISCLAIMER - PowerPoint PPT Presentation

Dec 29, 2022 •589 likes •838 views

CSE: VGW OTC: VGWCF CORPORATE PRESENTATION MARCH 2019 DISCLAIMER statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements and information contained in this Presentation are

  1. CSE: VGW OTC: VGWCF CORPORATE PRESENTATION MARCH 2019

  2. DISCLAIMER statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements and information contained in this Presentation are investigation and due diligence before making an investment. information that a prospective investor may require to fully evaluate an investment in the contemplated transaction. Prospective investors should conduct their own thorough organization, publicly referred to, or disclosed, in whole or in part, without express written permission. This presentation does not purport to be all inclusive or contain all the may not be used or relied upon for any purpose other than as specifically contemplated by a written agreement. The materials may not be circulated outside of the recipient’s could lose all or a substantial amount of his or her investment. This document is not an offer to sell (or solicitation of an offer to buy) any interest in the Company. These materials their investment and who fully understand and are willing to assume the risks involved. An investment may be considered to involve a substantial degree of risk, and an investor This investment is suitable only for sophisticated investors for whom an investment does not constitute a complete investment program, who do not require immediate liquidity for NOTICE TO RECIPIENT applicable securities legislation. Presentation and the Company assumes no obligation to update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by expressly qualified in their entirety by this cautionary statement. The forward-looking statements and information included in this Presentation are made as of the date of this There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such This Presentation contains forward-looking statements and forward-looking information. Often, but not always, forward-looking statements can be identified by the use of words or differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. as of any date subsequent to the date of this Presentation. Although the Company has attempted to identify important factors that could cause actual actions, events or results to products of the Company; competition; and anticipated and unanticipated costs. These forward-looking statements should not be re lied upon as representing the Company’s views necessary financing; the ability to complete a going public transaction; the ability to satisfy the requirements of a stock exchange; the economy generally; consumer interest in the Such forward-looking statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to: the ability of the Company to obtain Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this Presentation. prices; (D) expected growth in the number of users of medical and recreational marijuana anticipated; and (E) the expansion of t he Company’s business into other revenue streams. Company; (B) the intention to grow the business and operations of the Company; (C) anticipated timing for the availability of th e Company’s products to market and expected sale performance or achievements expressed or implied by the forward-looking statements and information. Examples of such statements include: (A) the financial forecast of the and risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, unknown words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be ach ieved. Forward-looking statements involve known and CSE:VGW, OTC:VGWCF 2

  3. Our mission is to become the world’s most trusted partner for best-in-class cannabis extraction, testing, formulations and product development. CSE:VGW, OTC:VGWCF 3

  4. Largest extraction producers, including Canopy, Tilray and Organigram Setting global standards, Valens Labs was the first ISO 17025 accredited lab for cannabis analyses and is endorsed by $100B+ Thermo Fisher Scientific as the Centre of Excellence in Plant Based Science. Operating in the highest margin sub-sector of the cannabis industry with low variability in costs. Substantial, reoccurring agreements with leading providing a clear revenue and cashflow path. company in Canada. Incorporated in 2012, Valens was granted the first Dealer’s License to process cannabis. Our R&D and testing process allows us to quickly identify market trends and adapt to a changing landscape. Decades of experience have resulted in a best in class proprietary extraction process that is optimized to produce consistently high quality products. CSE:VGW, OTC:VGWCF INVESTMENT as the global markets with efficiency at scale. is equipped to service Canadian demand as well At 240,000kg of capacity and growing, Valens First mover Most diverse extraction capabilities. In-house testing laboratory. High margins. High cashflow visibility. advantage. and processes. Providing customers with the widest variety of extraction techniques which allows them to produce the largest range of end products. Customized product development. Valens formulation and testing expertise allows for the production of a wide array of tinctures, capsules, concentrates, vapes, topicals, beverages and edibles. Proprietary technology HIGHLIGHTS 4

  5. 2016 71% OUR BELIEFS US MARKET SHAR E ROAD MAP CSE:VGW, OTC:VGWCF 75% 25% 53% 47% 29% “The future of cannabis in Canada is coming, and we are at the forefront.” *Valens forward-looking prediction in the short-term based on market research Source: Cowen Equity Research Report OIL BASED PRODUCTS FLOWER BASED PRODUCTS 2018 FUTURE* – Tyler Robson, CEO THE MARKET IS RAPIDLY MOVING TO OIL BASED PRODUCTS 5

  6. 1 2 3 4 EXTRACTION TESTING FORMULATION PRODUCT DEVELOPMENT CSE:VGW, OTC:VGWCF WHAT WE DO VALENS KEY FOCUS AREAS 6

  7. WHAT IS IT? CBG EXTRACTION CSE:VGW, OTC:VGWCF FATS LIPIDS WAXES CBN THC 1 CBD (DISTILLATE/ISOLATE) OIL REFINEMENT CANNABIS DRIED OIL WINTERIZATION OIL EXTRACTION 7

  8. Valens is the only company providing a wider variety of extraction methods Super/Sub and smell 1 Capsules Tinctures Vapes Edibles Critical CO2 Add back for Ethanol Hydrocarbon Solvent-less Terpene CSE:VGW, OTC:VGWCF EXTRACTION experience, flavour Live Resin allowing us to create more end products and ultimately meeting a larger number of customer needs. Beverages EXTRACTION Capsules Tinctures Vapes Topicals Edibles Hash Others Concentrates Vapes Shatter/Wax Full Spectrum Rosin WHAT IS OUR COMPETITIVE ADVANTAGE? 8

  9. RESIN or HOW WE GENERATE HIGH MARGINS EXTRACTION CSE:VGW, OTC:VGWCF 1 WHITE LABEL INCREASING MARGINS Revenue share Fee for service REFINED OIL Fee for service Fee for service development of oil for market Formulation and product to various refined stages Processing from crude oil flower to crude oil Processing from EXTRACTION 9

  10. A TRUSTED INDUSTRY PARTNER Trusted by industry-leading producers EXTRACTION CSE:VGW, OTC:VGWCF …AND MORE 1 GLOBAL INITIATIVES STRATEGIC PARTNERS -Greg Engel, CEO of Organigram and adult recreational cannabis markets. increasing demand of the global medical ongoing commitment to meeting the expertise to help ensure we deliver on our who can offer the capacity, quality and partnerships with companies like Valens A key element of [our] success is EXTRACTING FOR $45B WORTH OF MARKET CAP EXTRACTION PARTNERS high quality extracts Recognized for our expertise and ability to deliver annual quantities 2 to 4 year renewable contracts with minimum 10 • • •

  11. METALS PESTICIDES TERPENES RESIDUAL SOLVENTS MICROBIALS CANNABINOID PROFILES TESTING Consumer products are built on trust. This starts and ends with reliability and consistency. 2 Global Employees: 70,000 Market Cap: $104B USD Annual Revenue: $24B USD Fisher Scientific. Plant Based Science” by Thermo Named a “Center of Excellence in AND GLOBALLY FOR CANNABIS TESTING VALENS LABS: SETTING STANDARDS DOMESTICALLY testing (required by Health Canada for all producers) Additional revenue source through third-party lab laboratory results world-wide. the cannabis industry to increase the confidence in validated, standardized, and turnkey solutions for Working with Thermo Fisher Scientific to publish fully minimum of 5 days in as little as 24 hours. Valens can perform analyses that typically take a Utilizing the latest state of the art instrumentation, standard for testing laboratories. First ISO 17025 accredited lab - the global gold CSE:VGW, OTC:VGWCF 11

More recommend